Table 2

HPV status and telomerase PCR ELISA assay absorbance read at 450 nm with a reference wavelength of 690 (A₄₅₀) versus histological background of benign cervices (n=19) and histological diagnosis, stage, and lymph node status of cervical carcinoma (n=20)

Benign cervices				Cervical carcinoma
Case	Histological background	A₄₅₀	HPV	Case	Histological diagnosis	Stage	LN	A₄₅₀	HPV
ELISA, enzyme linked immunosorbent assay; LN, lymph node status; NA, information not available.
1	Uterovaginal prolapse	−0.032	L1	1	Squamous, non-keratinising	II	–	1.469	L1
2	Leiomyoma	−0.028	–	2	Squamous, non-keratinising	I	–	3.781	16
3	Leiomyoma	−0.069	–	3	Squamous, non-keratinising	IV	+	1.935	16
4	Benign ovarian teratoma	0.032	–	4	Squamous, keratinising	I	NA	1.841	16
5	Leiomyoma	0.081	–	5	Squamous, keratinising	I	–	0.173	16
6	Leiomyoma	0.135	–	6	Squamous, keratinising	I	–	0.209	L1
7	Leiomyoma	0.011	–	7	Squamous, non-keratinising	II	NA	3.163	16
8	Benign ovarian teratoma	−0.017	–	8	Squamous, non-keratinising	I	–	1.632	6
9	Uterovaginal prolapse	−0.020	–	9	Adenocarcinoma	II	–	0.178	16
10	Adenomyosis	0.038	–	10	Adenocarcinoma	I	–	0.017	16
11	Placenta praevia	−0.073	–	11	Squamous, non-keratinising	III	NA	0.238	16
12	Leiomyoma	0.349	–	12	Squamous, non-keratinising	II	NA	−0.006	L1
13	Ovarian serous cystadenoma	0.096	–	13	Squamous, non-keratinising	I	–	0.067	–
14	Uterovaginal prolapse	−0.002	–	14	Squamous, non-keratinising	I	–	21.790	L1
15	Leiomyoma	0.015	–	15	Lymphoepithelioma-like	I	–	0.013	16
16	Leiomyoma	0.019	–	16	Squamous, non-keratinising	III	NA	3.045	16
17	Endometrial polyp	0.006	–	17	Squamous, keratinising	I	–	0.075	16
18	Uterovaginal prolapse	0.012	–	18	Adenosquamous	I	–	0.222	–
19	Uterovaginal prolapse	0.003	–	19	Squamous, keratinising	II	NA	−0.001	16
				20	Squamous, keratinising	II	NA	0.630	16